PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-14.34%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-31.48%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
-7.72%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-7.72%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-31.48%
D&A reduction while TRAW shows 4.35% growth. Joel Greenblatt would examine efficiency.
7.65%
EBITDA growth 50-75% of TRAW's 10.70%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
7.72%
Operating income growth 50-75% of TRAW's 10.64%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
158.44%
Other expenses growth less than half of TRAW's 324.98%. David Dodd would verify if advantage is sustainable.
12.50%
Pre-tax income growth below 50% of TRAW's 69.02%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Net income growth below 50% of TRAW's 69.02%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
15.94%
EPS growth below 50% of TRAW's 76.69%. Michael Burry would check for structural issues.
15.94%
Diluted EPS growth below 50% of TRAW's 76.69%. Michael Burry would check for structural issues.
4.10%
Share count reduction exceeding 1.5x TRAW's 32.90%. David Dodd would verify capital allocation.
4.10%
Diluted share reduction exceeding 1.5x TRAW's 32.90%. David Dodd would verify capital allocation.